Consensus I-Mab

Equities

IMAB

US44975P1030

Market Closed - Nasdaq Other stock markets 01:30:00 03/05/2024 am IST			5-day change	1st Jan Change
1.765 ^USD	0.00%		-2.49%	-7.11%

18/04	Verastem Names John Hayslip as Chief Medical Officer	MT
15/04	I-Mab Announces Chief Medical Officer Changes	CI

Evolution of the average Target Price on I-Mab

Price target over the last 5 years

History of analyst recommendation changes

cb99c8733142947314a528d70d.efLO6x63IY8_QQdkBeZEWFpeMU2_hqO2aexspA5lTto.Id_jpmz-ZfUPc3UwX7JzCzA0ZSju_pT1M6QvyX49CbUes4_aSucVolQJSg~dd5f423bb72abd2bdf6ec7bb4455ea07

Analyst Recommendations on I-Mab

Piper Sandler Adjusts Price Target on I-Mab to $10 From $15, Maintains Overweight Rating	18/03	MT
Needham Cuts Price Target on I-Mab to $6 From $8, Maintains Buy Rating	15/03	MT
Needham Trims I-Mab Price Target to $23 From $24, Maintains Buy Rating	25/23/25	MT
HC Wainwright Adjusts Price Target on I-Mab to $18 From $25, Maintains Buy Rating	18/23/18	MT
Needham Lowers Price Target on I-Mab to $24 From $33, Maintains Buy Rating	03/23/03	MT
Piper Sandler Adjusts Price Target on I-Mab to $25 From $30, Maintains Overweight Rating	03/23/03	MT
HC Wainwright Adjusts Price Target on I-Mab to $25 From $45, Maintains Buy Rating	03/23/03	MT
MSCI ESG Updated I-Mab to 'A' Rating	08/23/08	AQ
MSCI ESG Updated I-Mab to "A" Rating	07/23/07	PR
I-Mab Says Combination Treatment for Myelodysplastic Syndrome Showed Overall Response Rate of 86.7% in Phase 2 Trial	12/22/12	MT
HC Wainwright Adjusts I-Mab's Price Target to $45 From $70, Maintains Buy Rating	31/22/31	MT
Needham Adjusts I-Mab's Price Target to $33 From $41, Reiterates Buy Rating	31/22/31	MT
Piper Sandler Adjusts I-Mab's Price Target to $30 From $35, Reiterates Overweight Rating	31/22/31	MT
Needham Lowers I-Mab's Price Target to $41 From $72, Maintains Buy Rating	17/22/17	MT
HC Wainwright Adjusts I-Mab's Price Target to $70 From $80, Keeps Buy Rating	31/22/31	MT
Piper Sandler Adjusts I-Mab's Price Target to $35 From $80, Reiterates Overweight Rating	31/22/31	MT
Needham Adjusts I-Mab's Price Target to $72 From $85, Reiterates Buy Rating	31/22/31	MT
HC Wainwright Adjusts I-Mab's Price Target to $80 from $95, Keeps Buy Rating	30/22/30	MT
Piper Sandler Adjusts I-Mab's Price Target to $80 From $90, Reiterates Overweight Rating	30/22/30	MT
SWS Research Starts I-Mab at Buy with $96 Price Target	09/21/09	MT
Needham Adjusts Price Target on I-Mab to $85 from $83, Keeps Buy Rating	01/21/01	MT
I MAB : HC Wainwright Adjusts I-Mab's Price Target to $95 from $75, Keeps Buy Rating	01/21/01	MT
I MAB : Cantor Fitzgerald Adjusts I-Mab PT to $95 From $90, Maintains Overweight Rating	13/21/13	MT
I MAB : Cantor Fitzgerald Adjusts I-Mab's Price Target to $90 From $76, Maintains Overweight Rating	10/21/10	MT
I MAB : Piper Sandler Adjusts I-Mab PT to $90 From $75, Maintains Overweight Rating	07/21/07	MT